Locally advanced cervical cancer
Conditions
Interventions
Test group:Camrelizumab in combination with concurrent chemoradiotherapy
Sponsors
Jiamusi Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Cervical cancer diagnosed histologically or cytologically (2018 FIGO stage IIB-IVA initial treatment) with measurable tumor lesions (spiral CT or MR Scan =10mm, meeting RECIST 1.1 criteria); 2. No previous immunotherapy; 3. Age: 18 ~ 70 years old; Female; 4.ECOG score: 0-2; 5. Expected survival > 3 months; 6. The functions of vital organs meet the following requirements (excluding the use of any blood components and cell growth factors during screening) : a) Neutrophil absolute count =1.5×109/L, platelet =100×109/L, hemoglobin =90g/dL; b) Bilirubin =1.5 ULN (patients with retrograde drainage may include); ALT and AST =5 ULN, albumin > 35g/ml, prothrombin time 60 mL/min; Patients volunteered to join the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, or those who are fertile but refuse to take contraceptive measures; 2. A history of other malignancies in the past 5 years; 3. Allergic to any tested drug and its excipients, with a history of severe allergy or contraindications to the tested drug; 4. Patients with uncontrolled, symptomatic brain metastases or a history of uncontrollable mental illness or with severe intellectual or cognitive dysfunction; 5. Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia and severe impairment of lung function; 6. Subjects with active, known, or suspected autoimmune diseases requiring hormone replacement therapy for hypothyroidism, skin conditions requiring no systemic therapy (such as vitiligo, psoriasis, or alopecia) are eligible; 7. Congestive heart failure, uncontrolled arrhythmia, myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months; 8. Severe active infections requiring intravenous antibiotic therapy occurred during the enrollment period; 9. Received or will receive live vaccine within 30 days prior to camrelizumab administration; 10. Known history of HIV infection; 11. Patients who cannot follow the trial protocol or cooperate with follow-up; 12.Researchers consider it inappropriate to participate in this study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate, DCR;Progression-free survival, PFS;Overall survival OS;safety; | — |
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate, ORR; | — |
Countries
China
Contacts
Public ContactXueliang Zhang
Jiamusi Cancer Hospital
Outcome results
None listed